Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib plus AK105 or AK105 alone in advanced MSI-H or dMMR solid tumors
CTR20200342Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, penpulimab in Nonhematologic neoplasms, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2020; status: terminated.
02
Drugs
anlotinibpenpulimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200342.